Advertisement

Organisation › Details
Galapagos N.V. (Euronext + Nasdaq: GLPG)
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and in Phase 2 in Crohn’s disease. GLPG1205, a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690 is a compound that targets pulmonary diseases and is currently in a Phase 1 trial. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. *
![]() |
Start | 1999-06-01 established_pre |
Group | Galapagos (Group) | |
Predecessor | Galapagos Genomics N.V. | |
![]() |
Industry | genomics/genetics |
![]() |
Person | Stoffels, Paul (Galapagos 202204– CEO before JnJ + Virco + Tibotec) |
Person 2 | Huston, Thad (Galapagos 202307– CFO + COO before Kite + LivaNova + 25y at JnJ) | |
![]() |
Region | Mechelen |
Country | Belgium | |
Street | Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3 | |
City | 2800 Mechelen | |
Tel | +32-15342900 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | F: 1,001 to 5,000 (2019-12-31) |
Currency | EUR | |
Annual sales | 895,890,000 (revenues + other income, total, consolidated (2019) 2019-12-31) | |
Profit | 149,845,000 (2019-12-31) | |
Cash | 5,780,832,000 (2019-12-31) | |
* Document for »About Section«: | ||
Record changed: 2023-09-25 |
Advertisement

More documents for Galapagos (Group)
- [1] Galapagos N.V.. (9/19/23). "Press Release: Galapagos Appoints Simon Sturge to Its Board of Directors". Mechelen....
- [2] Galapagos N.V.. (6/15/23). "Press Release: Galapagos Appoints Thad Huston as Chief Financial Officer and Chief Operating Officer". Mechelen....
- [3] Galapagos N.V.. (6/12/23). "Pressemitteilung: Galapagos Appoints Dr. Susanne Schaffert as Non-executive Independent Director to Its Board". Mechelen....
- [4] Galapagos N.V.. (6/21/22). "Press Release: Galapagos to Acquire CellPoint and AboundBio to Accelerate Access to Next-generation Cell Therapies". Mechelen, Leiden & Pittsburgh, PA....
- [5] Ryvu Therapeutics S.A.. (3/15/22). "Press Release: Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update". Krakow....
- [6] Galapagos N.V.. (1/26/22). "Press Release: Galapagos Appoints Paul Stoffels as Chief Executive Officer". Mechelen....
- [7] Ryvu Therapeutics S.A.. (12/14/21). "Press Release: Ryvu Announces Option to License Inflammation Program Exercised by Galapagos NV". Tübingen, Houston, TX & New York, NY....
- [8] Galapagos N.V.. (8/30/21). "Press Release: Galapagos Announces Planned Retirement of CEO". Mechelen....
- [9] Galapagos N.V.. (2/10/21). "Press Release: Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF". Foster City, CA & Mechelen....
- [10] Galapagos N.V.. (12/15/20). "Press Release: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (filgotinib)". Foster City, CA & Mechelen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top